Comparative Pharmacology
Head-to-head clinical analysis: STENDRA versus VIAGRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STENDRA versus VIAGRA.
STENDRA vs VIAGRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels in corpus cavernosum, leading to smooth muscle relaxation and blood flow into the penis.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
50 mg orally once as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability. Maximum dosing frequency: once per day.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Terminal elimination half-life approximately 4 hours (range 3–5 hours). No significant accumulation with recommended dosing.
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Renal (approximately 80% as metabolites, 20% as unchanged drug in feces), biliary/fecal (about 13% unchanged in feces). Total clearance 41 L/h.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor